<DOC>
	<DOCNO>NCT01305850</DOCNO>
	<brief_summary>This prospective , randomize , placebo control , multi-center clinical trial determine whether aliskiren aliskiren plus losartan enalapril plus losartan effect peritoneal membrane transportation .</brief_summary>
	<brief_title>The Effect Aliskiren Losartan Peritoneal Membrane Continuous Ambulatory Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Detailed description : Many peritoneal dialysis patient suffer uremia due inadequate dialysis volume overload cause failure peritoneal membrane transportation . One important etiology peritoneal membrane failure unavoidable use high glucose-containing dialysate solution induces injury mesothelial cell . Previous data find injured mesothelial cell produce Angiotensin II induce peritoneal inflammation fibrosis . Blockade renin-angiotensin system angiotensin-converting enzyme inhibition angiotensin receptor antagonism play major role slow effect . Many trial animal study prove benefit angiotensin-converting enzyme inhibition angiotensin receptor antagonism preservation peritoneal membrane clinical evidence human controversy past . Recently data demonstrate role angiotensin-converting enzyme inhibition angiotensin receptor antagonism slow peritoneal membrane dysfunction view anatomy solute transportation ( abstract presentation American Society Nephrology 2010 ) . These available data confirm renin-angiotensin system blockages benefit . Nowadays , new class antihypertensive drug , call direct renin inhibitor . It block ( pro ) renin active site rate- limiting step renin-angiotensin system . We 're interesting drug wonder slow peritoneal membrane dysfunction continuous ambulatory peritoneal dialysis patient . Therefore , design study show effect aliskiren alone combination angiotensin receptor antagonism slow peritoneal membrane dysfunction naive continuous ambulatory peritoneal dialysis patient several hospital . Our study take 1 year duration use modify peritoneal equilibrium test dialysate cancer antigen 125 ( CA125 ) index peritoneal membrane transportation .</detailed_description>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . All patient receive continuous ambulatory peritoneal dialysis less one half year 2 . Subjects either sex , 20 year old 3 . Hypertension 4 . Provision write informed consent subject guardian 1 . No history take angiotensin convert enzyme inhibitor angiotensinreceptor blocker aldosterone antagonist least 2 month 2 . Serum potassium 5.5 mEq/L 3 . History renal artery stenosis 4 . Peritonitis volume overload within precede 1 month 5 . Myocardial infarction within precede 6 month clinically significant valvular disease active cardiovascular disease 6 . History malignant hypertension hypertensive encephalopathy cerebrovascular accident within precede 6 month 7 . Any condition may preclude patient remain study , alcohol drug abuse , chronic liver disease , malignant disease , psychiatric disorder 8 . History allergy intolerance angiotensin convert enzyme inhibitor angiotensin receptor blocker 9 . Hypotension define systolic blood pressure le 90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Losartan</keyword>
	<keyword>Peritoneal membrane dysfunction</keyword>
</DOC>